Physician profile
Paul A Johnson
NPI 1720043045
$3,303.55
in general payments reported to CMS, 2019-2025
31 companies · $553 in 2025
The $553 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $386 · 2021: $572 · 2022: $411 · 2023: $496 · 2024: $441 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.44 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.12 | 2019-2025 | |
| Janssen Biotech, INC. | $249.89 | 2019-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $174.76 | 2019-2024 | Dificid, Zinplava |
| Gilead Sciences, INC. | $161.41 | 2019-2023 | |
| Pfizer INC. | $150.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.41 | 2019-2024 | Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.95 | 2020-2025 | Xifaxan |
| Boston Scientific Corporation | $138.07 | 2019-2023 | Exalt Model D |
| Intercept Pharmaceuticals, INC. | $107.14 | 2021-2025 | Ocaliva |
| Stryker Corporation | $93.90 | 2025 | Flowtriever |
| Nestle Healthcare Nutrition INC. | $89.92 | 2021-2022 | |
| Lilly USA, LLC | $66.75 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $61.24 | 2023 | Dupixent |
| Celgene Corporation | $57.81 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $51.93 | 2024-2025 | Iqirvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $46.22 | 2021-2025 | Endoflip |
| Madrigal Pharmaceuticals | $35.18 | 2025 | Rezdiffra |
| Celltrion USA INC. | $30.91 | 2024-2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $26.68 | 2023 | |
| Qol Medical, LLC | $21.12 | 2024 | Sucraid |
| Ardelyx, INC. | $20.42 | 2023 | Ibsrela |
| Novo Nordisk INC | $19.84 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $17.31 | 2024 | Sutab, Suflave |
| Biocon Biologics INC | $16.56 | 2024 | Hulio |
| Conmed Corporation | $16.50 | 2019 | |
| Covidien LP | $15.76 | 2020 | |
| Organon LLC | $15.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $12.08 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.35 | 2019 | |
| Alfasigma USA, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.